Caption Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Caption Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	-$2.03M	–	1346
2023 Q4	$2.03M	Buy	+100,000	New	+$1.32M	0.03%	614
2023 Q3	–	Sell	-71,900	Closed	-$1.3M	–	1350
2023 Q2	$1.3M	Buy	+71,900	New	+$1.32M	0.02%	602

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's FDMT Position: Q3 2023 in Review

Caption Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2023, closing a stake of 11,944 shares — an estimated $216K sold.

Caption Management first reported a position in FDMT in Q2 2023 and held it in 1 quarter. The position peaked at $216K in Q2 2023. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2023.

Caption Management reported no remaining 4D Molecular Therapeutics position as of Q3 2023 after selling out during the quarter.
Caption Management sold 11,944 4D Molecular Therapeutics shares in Q3 2023, an estimated $216K.
Caption Management first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 1 quarter.
Caption Management's 4D Molecular Therapeutics position peaked at $216K in Q2 2023.
110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2023.

Based on Caption Management's 13F filing for Q3 2023, filed 14 Nov 2023.